McKesson Co. (NYSE:MCK) Director N Anthony Coles sold 1,350 shares of the business’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $128.69, for a total transaction of $173,731.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NYSE:MCK opened at $125.50 on Friday. The firm has a market capitalization of $24.66 billion, a P/E ratio of 9.94, a price-to-earnings-growth ratio of 1.32 and a beta of 1.25. McKesson Co. has a 1 year low of $122.49 and a 1 year high of $178.86. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.00 and a quick ratio of 0.57.
McKesson (NYSE:MCK) last issued its quarterly earnings data on Thursday, July 26th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.89 by $0.01. The firm had revenue of $52.61 billion during the quarter, compared to analysts’ expectations of $52.91 billion. McKesson had a negative net margin of 0.18% and a positive return on equity of 25.19%. McKesson’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.47 earnings per share. equities analysts anticipate that McKesson Co. will post 13.33 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 1st. Investors of record on Tuesday, September 4th will be issued a $0.39 dividend. The ex-dividend date is Friday, August 31st. This is a boost from McKesson’s previous quarterly dividend of $0.34. This represents a $1.56 dividend on an annualized basis and a yield of 1.24%. McKesson’s dividend payout ratio is currently 12.36%.
Several research firms have recently commented on MCK. Leerink Swann set a $160.00 price target on shares of McKesson and gave the company a “market perform” rating in a report on Tuesday, May 29th. Robert W. Baird cut shares of McKesson from an “outperform” rating to a “neutral” rating in a report on Friday, July 20th. Royal Bank of Canada restated a “hold” rating and set a $152.00 price target on shares of McKesson in a report on Friday, July 27th. JPMorgan Chase & Co. lowered their price target on shares of McKesson from $181.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday, July 27th. Finally, Standpoint Research upgraded shares of McKesson from a “hold” rating to a “buy” rating in a report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $154.30.
A number of large investors have recently modified their holdings of MCK. Boston Partners lifted its position in McKesson by 54.5% during the 2nd quarter. Boston Partners now owns 6,237,042 shares of the company’s stock worth $832,021,000 after acquiring an additional 2,200,669 shares during the last quarter. Vulcan Value Partners LLC lifted its position in McKesson by 7.8% during the 2nd quarter. Vulcan Value Partners LLC now owns 3,768,099 shares of the company’s stock worth $502,664,000 after acquiring an additional 273,090 shares during the last quarter. Pzena Investment Management LLC lifted its position in McKesson by 7.6% during the 2nd quarter. Pzena Investment Management LLC now owns 2,836,710 shares of the company’s stock worth $378,417,000 after acquiring an additional 201,062 shares during the last quarter. Kiltearn Partners LLP lifted its position in McKesson by 6.3% during the 1st quarter. Kiltearn Partners LLP now owns 1,914,898 shares of the company’s stock worth $269,350,000 after acquiring an additional 112,800 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in McKesson by 13.3% during the 1st quarter. Wells Fargo & Company MN now owns 1,859,883 shares of the company’s stock worth $262,000,000 after acquiring an additional 218,530 shares during the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Recommended Story: Market Capitalization and Individual Investors
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.